<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609154</url>
  </required_header>
  <id_info>
    <org_study_id>1999-041</org_study_id>
    <secondary_id>Sub-study 4</secondary_id>
    <nct_id>NCT00609154</nct_id>
  </id_info>
  <brief_title>Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates</brief_title>
  <official_title>Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on&#xD;
      maintaining the function and health of the insulin producing beta cells. This hormone is&#xD;
      known to increase the production rate of new insulin as well as increase the release of&#xD;
      insulin into the blood. We will measure the rate of new insulin production in subjects with&#xD;
      Type 2 diabetes compared to non diabetic subjects. We hypothesize that subjects with Type 2&#xD;
      diabetes make less insulin in response to GLP-1 compared to non diabetic subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin biosynthesis rate</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetic Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who are non-diabetic will serve as control. treatment is matched to experimental group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucagon like peptide-1</intervention_name>
    <description>GLP-1 1 pmole/kg/min</description>
    <arm_group_label>Diabetic Group</arm_group_label>
    <arm_group_label>Non-diabetic Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glucose control</intervention_name>
    <description>glucose without GLP-1</description>
    <arm_group_label>Diabetic Group</arm_group_label>
    <arm_group_label>Non-diabetic Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes&#xD;
&#xD;
          -  Non diabetic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking medication such as thiazolidinediones, metformin, Exenatide, or&#xD;
             sitagliptin&#xD;
&#xD;
          -  Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD),&#xD;
             or chronic renal failure (CRF)&#xD;
&#xD;
          -  Anemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicinie</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>biosynthesis</keyword>
  <keyword>Non diabetic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

